Renovorx presenting phase iii clinical trial interim analysis data of the tiger-pac study at american association for cancer research annual meeting underway in orlando, florida

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that poster #ct084 is presenting detailed, open label, phase iii tiger-pac study interim data analysis of its innovative renovogem therapy for pancreatic cancer patients at the american association for cancer research (aacr) annual meeting, on monday, april 17, 2023, at 9:00 am et in orlando, florida.
RNXT Ratings Summary
RNXT Quant Ranking